Medical marijuana company Creso Pharma (ASX:CPH) has just entered the emerging $100 billion global market for psychedelic medicine with acquisition of Canada-based Halucenex Life Sciences.

The agreement provides Creso Pharma with entry into the emerging global market for psychedelics medicines – estimated to be worth up to US$100Bn.

The acquisition marks the first fully-owned psychedelic medicines company on the ASX.

Halucenex is a Psychedelic-Assisted Psychotherapy (PAP) company. As a result of the acquisition, it will benefit from significant synergies including Creso Pharma’s experienced pharmaceutical product development team, industry leading advisers, a comprehensive global distribution network and a top-tier premium cannabis cultivation facility.

Watch the interview below with Creso strategic advisor, Bruce Linton, and  founder of Canopy Growth (NYSE:CGC), the world’s largest cannabis company share his thoughts on the acquisition.

This article was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.